Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data

Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Progress in neuro-psychopharmacology & biological psychiatry 2013-08, Vol.45, p.178-182
Hauptverfasser: Tsuboi, Takashi, Bies, Robert R., Suzuki, Takefumi, Mamo, David C., Pollock, Bruce G., Graff-Guerrero, Ariel, Mimura, Masaru, Uchida, Hiroyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 182
container_issue
container_start_page 178
container_title Progress in neuro-psychopharmacology & biological psychiatry
container_volume 45
creator Tsuboi, Takashi
Bies, Robert R.
Suzuki, Takefumi
Mamo, David C.
Pollock, Bruce G.
Graff-Guerrero, Ariel
Mimura, Masaru
Uchida, Hiroyuki
description Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated. The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.). The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia. •We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.
doi_str_mv 10.1016/j.pnpbp.2013.05.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500791253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S027858461300105X</els_id><sourcerecordid>1500791253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhi0EomnhFyAhX5C4JPhj7d1F4hCFQitV4lLO1qw9qzjaD2M7Remvx2kC3ODkkfyMPe88hLzhbMUZ1x92qzCFLqwE43LF1Ipx9owseFM3y0pw_ZwsmCi1aip9QS5T2jFWSCZfkgsha1FzqRbk8eYQMIY4D2Czn3D0QGFyFFP2I2R01M0BxnJDPwsa0WLIc6SztfsAkz1QP9EA2eOUE_3p85Ymu_WPc9hGnDx8pOsJhkPyic49zVukm_X97TV1kOEVedHDkPD1-bwi379c329ulnffvt5u1ndLW-k6LzttwQIqLVTX6JY3bdV23EkNWDXQI1oNnaqdU1XbIuMKlXRYS2FZW0nZyCvy_vRuSfljX4KZ0SeLwwATzvtkuGKsbrlQ8v9oxQUvk-iqoPKE2jinFLE3IZaNxYPhzBz9mJ158mOOfgxTpvgpXW_PH-y7Ed2fnt9CCvDuDECyMPSxLNmnv1ytWdvqY6hPJw7L5h48RpNskWDR-SIpGzf7fw7yC31dsBE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412156264</pqid></control><display><type>article</type><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</creator><creatorcontrib>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</creatorcontrib><description>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated. The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.). The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia. •We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2013.05.010</identifier><identifier>PMID: 23727135</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - blood ; Antipsychotic Agents - pharmacology ; Benzodiazepines - adverse effects ; Benzodiazepines - blood ; Benzodiazepines - pharmacology ; Biological and medical sciences ; CATIE ; Data processing ; Dopamine D2 receptor occupancy ; Endocrinopathies ; Female ; Humans ; Hyperprolactinemia ; Hyperprolactinemia - blood ; Hyperprolactinemia - chemically induced ; Hyperprolactinemia - complications ; Hyperprolactinemia - metabolism ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Pharmacology. Drug treatments ; Piperazines - adverse effects ; Piperazines - blood ; Piperazines - pharmacology ; Predictive Value of Tests ; Prolactin - blood ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Receptors, Dopamine D2 - drug effects ; Risperidone - adverse effects ; Risperidone - blood ; Risperidone - pharmacology ; Schizophrenia ; Schizophrenia - blood ; Schizophrenia - complications ; Schizophrenia - metabolism ; Sensitivity and Specificity ; Thiazoles - adverse effects ; Thiazoles - blood ; Thiazoles - pharmacology</subject><ispartof>Progress in neuro-psychopharmacology &amp; biological psychiatry, 2013-08, Vol.45, p.178-182</ispartof><rights>2013 The Authors</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</citedby><cites>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2013.05.010$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27609968$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23727135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsuboi, Takashi</creatorcontrib><creatorcontrib>Bies, Robert R.</creatorcontrib><creatorcontrib>Suzuki, Takefumi</creatorcontrib><creatorcontrib>Mamo, David C.</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Graff-Guerrero, Ariel</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><creatorcontrib>Uchida, Hiroyuki</creatorcontrib><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><title>Progress in neuro-psychopharmacology &amp; biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated. The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.). The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia. •We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - blood</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - blood</subject><subject>Benzodiazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>CATIE</subject><subject>Data processing</subject><subject>Dopamine D2 receptor occupancy</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperprolactinemia</subject><subject>Hyperprolactinemia - blood</subject><subject>Hyperprolactinemia - chemically induced</subject><subject>Hyperprolactinemia - complications</subject><subject>Hyperprolactinemia - metabolism</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - blood</subject><subject>Piperazines - pharmacology</subject><subject>Predictive Value of Tests</subject><subject>Prolactin - blood</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Receptors, Dopamine D2 - drug effects</subject><subject>Risperidone - adverse effects</subject><subject>Risperidone - blood</subject><subject>Risperidone - pharmacology</subject><subject>Schizophrenia</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - metabolism</subject><subject>Sensitivity and Specificity</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - blood</subject><subject>Thiazoles - pharmacology</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vEzEQhi0EomnhFyAhX5C4JPhj7d1F4hCFQitV4lLO1qw9qzjaD2M7Remvx2kC3ODkkfyMPe88hLzhbMUZ1x92qzCFLqwE43LF1Ipx9owseFM3y0pw_ZwsmCi1aip9QS5T2jFWSCZfkgsha1FzqRbk8eYQMIY4D2Czn3D0QGFyFFP2I2R01M0BxnJDPwsa0WLIc6SztfsAkz1QP9EA2eOUE_3p85Ymu_WPc9hGnDx8pOsJhkPyic49zVukm_X97TV1kOEVedHDkPD1-bwi379c329ulnffvt5u1ndLW-k6LzttwQIqLVTX6JY3bdV23EkNWDXQI1oNnaqdU1XbIuMKlXRYS2FZW0nZyCvy_vRuSfljX4KZ0SeLwwATzvtkuGKsbrlQ8v9oxQUvk-iqoPKE2jinFLE3IZaNxYPhzBz9mJ158mOOfgxTpvgpXW_PH-y7Ed2fnt9CCvDuDECyMPSxLNmnv1ytWdvqY6hPJw7L5h48RpNskWDR-SIpGzf7fw7yC31dsBE</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Tsuboi, Takashi</creator><creator>Bies, Robert R.</creator><creator>Suzuki, Takefumi</creator><creator>Mamo, David C.</creator><creator>Pollock, Bruce G.</creator><creator>Graff-Guerrero, Ariel</creator><creator>Mimura, Masaru</creator><creator>Uchida, Hiroyuki</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130801</creationdate><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><author>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - blood</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - blood</topic><topic>Benzodiazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>CATIE</topic><topic>Data processing</topic><topic>Dopamine D2 receptor occupancy</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperprolactinemia</topic><topic>Hyperprolactinemia - blood</topic><topic>Hyperprolactinemia - chemically induced</topic><topic>Hyperprolactinemia - complications</topic><topic>Hyperprolactinemia - metabolism</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - blood</topic><topic>Piperazines - pharmacology</topic><topic>Predictive Value of Tests</topic><topic>Prolactin - blood</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Receptors, Dopamine D2 - drug effects</topic><topic>Risperidone - adverse effects</topic><topic>Risperidone - blood</topic><topic>Risperidone - pharmacology</topic><topic>Schizophrenia</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - metabolism</topic><topic>Sensitivity and Specificity</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - blood</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuboi, Takashi</creatorcontrib><creatorcontrib>Bies, Robert R.</creatorcontrib><creatorcontrib>Suzuki, Takefumi</creatorcontrib><creatorcontrib>Mamo, David C.</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Graff-Guerrero, Ariel</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><creatorcontrib>Uchida, Hiroyuki</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuboi, Takashi</au><au>Bies, Robert R.</au><au>Suzuki, Takefumi</au><au>Mamo, David C.</au><au>Pollock, Bruce G.</au><au>Graff-Guerrero, Ariel</au><au>Mimura, Masaru</au><au>Uchida, Hiroyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</atitle><jtitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>45</volume><spage>178</spage><epage>182</epage><pages>178-182</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated. The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.). The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia. •We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23727135</pmid><doi>10.1016/j.pnpbp.2013.05.010</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-5846
ispartof Progress in neuro-psychopharmacology & biological psychiatry, 2013-08, Vol.45, p.178-182
issn 0278-5846
1878-4216
language eng
recordid cdi_proquest_miscellaneous_1500791253
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adolescent
Adult
Adult and adolescent clinical studies
Aged
Antipsychotic Agents - adverse effects
Antipsychotic Agents - blood
Antipsychotic Agents - pharmacology
Benzodiazepines - adverse effects
Benzodiazepines - blood
Benzodiazepines - pharmacology
Biological and medical sciences
CATIE
Data processing
Dopamine D2 receptor occupancy
Endocrinopathies
Female
Humans
Hyperprolactinemia
Hyperprolactinemia - blood
Hyperprolactinemia - chemically induced
Hyperprolactinemia - complications
Hyperprolactinemia - metabolism
Hypothalamus. Hypophysis. Epiphysis (diseases)
Male
Medical sciences
Middle Aged
Neuropharmacology
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Pharmacology. Drug treatments
Piperazines - adverse effects
Piperazines - blood
Piperazines - pharmacology
Predictive Value of Tests
Prolactin - blood
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Receptors, Dopamine D2 - drug effects
Risperidone - adverse effects
Risperidone - blood
Risperidone - pharmacology
Schizophrenia
Schizophrenia - blood
Schizophrenia - complications
Schizophrenia - metabolism
Sensitivity and Specificity
Thiazoles - adverse effects
Thiazoles - blood
Thiazoles - pharmacology
title Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A17%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperprolactinemia%20and%20estimated%20dopamine%20D2%20receptor%20occupancy%20in%20patients%20with%20schizophrenia:%20Analysis%20of%20the%20CATIE%20data&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Tsuboi,%20Takashi&rft.date=2013-08-01&rft.volume=45&rft.spage=178&rft.epage=182&rft.pages=178-182&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2013.05.010&rft_dat=%3Cproquest_cross%3E1500791253%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412156264&rft_id=info:pmid/23727135&rft_els_id=S027858461300105X&rfr_iscdi=true